| First Author | Inoue-Yamauchi A | Year | 2018 |
| Journal | Carcinogenesis | Volume | 39 |
| Issue | 1 | Pages | 28-35 |
| PubMed ID | 29040439 | Mgi Jnum | J:256355 |
| Mgi Id | MGI:6111570 | Doi | 10.1093/carcin/bgx112 |
| Citation | Inoue-Yamauchi A, et al. (2018) Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis. Carcinogenesis 39(1):28-35 |
| abstractText | Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity, is an emerging risk factor for hepatocellular carcinoma (HCC). Accumulating evidence has shown that chronic inflammation represents a plausible link between obesity and HCC and that the pro-inflammatory cytokine interleukin (IL)-6 contributes to the development of obesity-related HCC. In the present study, we aimed to examine the therapeutic potential of the omega-3 polyunsaturated fatty acid, eicosapentaenoic acid (EPA), which exerts anti-inflammatory effects. The results showed that the development of carcinogen-induced HCC was significantly less in mice fed a high-fat diet (HFD) supplemented with EPA than in those fed HFD only, suggesting that EPA attenuates the development of obesity-related HCC. Although EPA did not appear to affect obesity-linked inflammation, it suppressed the activation of the pro-tumorigenic IL-6 effector STAT3, contributing to the inhibition of tumor growth. These findings suggest a clinical implication of EPA as a treatment for obesity-related HCC. |
